header logo image


Page 369«..1020..368369370371..380390..»

182 Genes Identified That Regulate Interactions Between Cancer Cells and T Cells – Technology Networks

September 29th, 2020 3:53 pm

Toronto scientists have mapped the genes allowing cancer cells to avoid getting killed by the immune system in a finding that paves the way for the development of immunotherapies that would be effective for larger patient populations and across different tumour types.

"Over the last decade, different forms of immunotherapy have emerged as really potent cancer treatments but the reality is that they only generate durable responses in a fraction of patients and not for all tumour types," says Jason Moffat, a professor of molecular genetics in the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto who led the work.

The study also revealed the need for new therapy to take into account the genetic composition of tumours because of mutations in the cancer cells that can potentially make the disease worse in response to treatment, often referred to as cancer resistance mutations.

"It's very important to understand at the molecular level how cancer develops resistance to immunotherapies in order to make them more broadly available. Advances in systematic genetic approaches have let us key in on genes and molecular pathways that are commonly involved in resistance to therapy," says Moffat, who holds Canada Research Chair in Functional Genomics of Cancer.

In immunotherapy, a patient's own immune cells, known as T killer cells, are engineered to find and destroy cancer. But treatment resistance has precluded its use in most patients, especially those with solid tumours.

"It's an ongoing battle between the immune system and cancer, where the immune system is trying to find and kill the cancer whereas the cancer's job is to evade that killing," says Keith Lawson, a co-lead author completing a PhD in Moffat's lab as part of his medical training in the Surgeon-Scientist Program at U of T's Faculty of Medicine.

Tumour heterogeneity--genetic variation in tumour cells within and across individuals that can impact therapy response--further complicates things.

"It's important to not just find genes that can regulate immune evasion in one model of cancer, but what you really want are to find those genes that you can manipulate in cancer cells across many models because those are going to make the best therapeutic targets," says Lawson.

The team, including collaborators from Agios Pharmaceuticals in Cambridge, Massachusetts, looked for genes that regulate immune evasion across six genetically diverse tumor models derived from breast, colon, kidney and skin cancer. The cancer cells were placed in a dish alongside the T cells engineered to kill them, where the ensuing onslaught served as a baseline. The researchers next deployed the gene editing tool CRISPR to switch off one-by-one every gene in the cancer cells and measured the resulting deviations from the killing baseline.

They identified 182 "core cancer intrinsic immune evasion genes" whose deletion makes the cells either more sensitive or more resistant to T cell attack. Among the resisters were all the genes known to develop mutations in patients who stopped responding to immunotherapy, giving the researchers confidence that their approach worked.

Many of the found genes had no previous links to immune evasion.

"That was really exciting to see, because it means that our dataset was very rich in new biological information", says Lawson.

Genes involved in autophagy, a process when cells ramp up recycling their components to mitigate damage following stress, came up as key for immune evasion. This raises a possibility that cancer's susceptibility to immunotherapy could be boosted by targeting its autophagy genes.

But as the researchers delved deeper, they found that deleting certain autophagy genes in pairs rendered the cells resistant to T cell killing. It means that if a tumour already harbors a mutation in one autophagy gene, a treatment that combines immunotherapy with a drug targeting another autophagy gene could make the disease worse in that patient.

"We found this complete inversion of gene dependency", says Moffat. "We did not anticipate this at all. What it shows us is that genetic context, what mutations are present, very much dictates whether the introduction of the second mutations will cause no effect, resistance or sensitivity to therapy".

As more research explores combinatorial effects of mutations across different types of cancer cells, it should become possible to predict from a tumour's DNA what type of therapy will be most effective.

Reference: Lawson KA, Sousa CM, Zhang X, et al.Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature, 2020. doi:10.1038/s41586-020-2746-2

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
182 Genes Identified That Regulate Interactions Between Cancer Cells and T Cells - Technology Networks

Read More...

Molecular Biomarkers Market Incredible Possibilities, Growth Analysis and Forecast To 2026 |112233 – The Daily Chronicle

September 29th, 2020 3:53 pm

Molecular Biomarkers Market Overview 2020 2025

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Molecular Biomarkers Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/66212

Key Competitors of the Global Molecular Biomarkers Market are: , Alere, Atossa Genetics, Biophysical, Abbott, BioCept, BioTheranostics, DiagnoCure, GenomeDx, Genomic Health, Gen-Probe, Life Technologies, 20/20 GeneSystems, Cynvenio, Dako (Agilent), Epic Sciences, Foundation Medicine, Genomic Health, Molecular Response, Nodality, PGD

Historical data available in the report elaborates on the development of the Molecular Biomarkers on national, regional and international levels. Molecular Biomarkers Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:GenomicsProteomicsOthers

Major Applications of Molecular Biomarkers covered are:MedicineBiologyOthers

This study report on global Molecular Biomarkers market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/66212

The fundamental purpose of Molecular Biomarkers Market report is to provide a correct and strategic analysis of the Molecular Biomarkers industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Molecular Biomarkers market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Molecular-Biomarkers-Market-66212

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

See the original post:
Molecular Biomarkers Market Incredible Possibilities, Growth Analysis and Forecast To 2026 |112233 - The Daily Chronicle

Read More...

Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment…

September 29th, 2020 3:53 pm

LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, todayannounced the receipt of Ethics Committee approval in the U.K. for the Companys Cancer Appetite Recovery Study (CAReS) entitled A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss. Barry J. A. Laird, M.D. of the Institute of Genetics and Molecular Medicine at the University of Edinburgh and St. Columbias Hospice Reader in Palliative Medicine, will serve as the coordinating investigator. ART27.13 is a highly potent, peripherally restricted synthetic, dual cannabinoid agonist believed to target peripheral CB1/CB2 receptors, and has the potential to increase appetite and food intake. Artelo intends to initially develop ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss.

Receiving Ethics Committee approval is an essential step towards commencing our CAReS trial in the UK, stated Steven D. Reich, M.D., Artelos Chief Medical Officer. We are very pleased to have Dr. Laird as our Coordinating Investigator as we believe that his extensive knowledge of and focus on palliative medicine as well as his direct expertise in clinical trials evaluating treatments for anorexia will be invaluable as we evaluate ART27.13. We are working diligently on securing the additional regulatory requisite approvals which will enable us to open our clinical sites and initiate patient enrollment later this year.

"As an academic clinician, I am passionate about improving symptoms in people with life-limiting illness and I am honored to be working with Artelo on this exciting program and the CAReS clinical trial, stated Dr. Laird. My teams overarching goal is to help find therapies which improve the care of patients with cancer and I look forward to evaluating the potential of ART27.13 to reduce the devastating symptoms and improve quality of life of those suffering from this disease."

About the CAReS Study CAReS is a Phase 1/2 clinical trial of the synthetic cannabinoid ART27.13 in patients with cancer anorexia and weight loss, which will enroll up to 49 subjects, initially in clinical trial sites located in the U.K. The primary endpoint in Phase 1 of the study is to determine the most effective and safe dose of ART27.13 to be utilized in Phase 2. The primary endpoint in Phase 2 of the study is to determine point estimates of activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia.

About ART27.13ART27.13 is a potent, peripherally restricted dual synthetic agonist of the CB1/CB2 receptors. Existing ART27.13 clinical data suggests meaningful potential for the treatment of cancer-related anorexia and weight loss. In five Phase I clinical studies including over 200 subjects, ART27.13 previously demonstrated a statistically significant and dose-dependent increase in body weight in subjects without cancer. Artelo plans to advance ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss.

About Artelo Biosciences, Inc. Artelo Biosciences, Inc.is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, post-traumatic stress disorder, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and medical experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available atwww.artelobio.comand Twitter:@ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Companys product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Companys filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email:ARTL@crescendo-ir.com

Read more:
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment...

Read More...

Global Anal Cancer Pipeline Report 2020: Breakdown by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule…

September 29th, 2020 3:53 pm

Dublin, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The "Anal Cancer - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Anal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews the key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 19, 18, 2 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to Buy

Key Topics Covered:

Introduction

Anal Cancer - Therapeutics Assessment

Anal Cancer - Companies Involved in Therapeutics Development

Anal Cancer - Dormant Projects

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jteb4n

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original here:
Global Anal Cancer Pipeline Report 2020: Breakdown by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule...

Read More...

Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. – UroToday

September 29th, 2020 3:53 pm

Urothelial carcinoma of the bladder (UCB) exhibits significant sexual dimorphism in the incidence, etiology, and response to intravesical immunotherapy. Environmental factors such as tobacco use and clinical management issues such as delayed presentation have widely been associated with sex differences in UCB outcomes. Emerging findings from immune checkpoint blockade trials are suggestive of differential outcomes in females compared with males. Sex-specific differences in the way immune system functions and responds to pathogenic insults are well established. As such, an in-depth understanding of the genetic and epigenetic factors contributing to sex-associated differences in response to immunomodulatory therapies is needed urgently for improved management of UCB.

To review the associations between patient sex and clinical outcomes, with a focus on the incidence, host intrinsic features, and response to therapies in UCB.

Using the PubMed database, this narrative review evaluates published findings from mouse model-based and clinical cohort studies to identify factors associated with sex and clinical outcomes in bladder cancer. A scoping review of the key findings on epidemiology, genetic, hormonal, immune physiology, and clinical outcomes was performed to explore potential factors that could have implications in immunomodulatory therapy design.

Sex-associated differences in UCB incidence and clinical outcomes are influenced by sex hormones, local bladder resident immune populations, tumor genetics, and bladder microbiome. In the context of therapeutic outcomes, sex differences are prominent in response to bacillus Calmette-Gurin immunotherapy used in the treatment of non-muscle-invasive bladder cancer. Similarly, with respect to tumor molecular profiles in muscle-invasive bladder cancer, tumors from females show enrichment of the basal subtype.

Among proposed tumor/host intrinsic factors that may influence response to immune-based therapies, patient sex remains a challenging consideration that deserves further attention. Evidence to date supports a multifactorial origin of sexual dimorphism in the incidence and outcomes of UCB.

In this review, we highlight the sex-associated host and tumor intrinsic features that may potentially drive differential disease progression and therapeutic response in urothelial carcinoma of the bladder.

European urology oncology. 2020 Sep 20 [Epub ahead of print]

Madhuri Koti, Molly A Ingersoll, Shilpa Gupta, Christa M Lam, Xue Li, Ashish M Kamat, Peter C Black, D Robert Siemens

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada; Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada; Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada; Department of Urology, Queen's University, Kingston, Ontario, Canada. Electronic address: ., Department of Immunology, Institut Pasteur, Paris, France., Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Department of Urology and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Department of Urology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Department of Urology, Queen's University, Kingston, Ontario, Canada.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/32967818

See the rest here:
Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. - UroToday

Read More...

Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,…

September 29th, 2020 3:53 pm

Pune, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The global genomics market size is projected to reach USD 82.60 billion by the end of 2027. The massive investments in the research and development of efficient products will have a massive impact on the growth of the market in the coming years.

According to a report published by Fortune Business Insights, titled Genomics Market Size, Share & COVID-19 Impact Analysis, By Type (Products (Instruments & Software and Consumables) and Services), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Microarray, Sanger Sequencing, and Others), By Application (Diagnostics, Research, and Others), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)), and Regional Forecast, 2020-2027, the market was worth USD 18.85 billion in 2019 and will exhibit a CAGR of 19.5% during the forecast period 2020-2027.

Genomics is a concept that involves the human gene and sequencing for treatment and study of several diseases or potential diseases. The study of human genetics helps identify and track critical diseases, with equal focus on the qualities and behaviour of a specific individual. In the past few years, genomics has contributed to the growth of numerous similar branches including the popular precision medicine.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941

The massive investments in the research and development of genomics and genomic sequencing will have a positive impact on the growth of the overall market in the coming years. The presence of several large scale companies has had a massive impact on the growth of the market in recent years and the influx of start-ups will create opportunities for growth in the foreseeable future.

Recent Clinical Studies have Indicated the Potential of Genomics to Tracking Patterns of Covid-19 Spread

The recent coronavirus outbreak has created a sense of panic among businesses across the world. Although healthcare industry has witnessed a contrasting impact, as compared to a few other sectors, there has been a recent surge in the need for healthcare professionals. The lack of skilled labour is consequential to the hesitancy among workers due to the severity of the disease. Although there are several ongoing research activities associated with the treatment of the coronavirus, there has been little success in this field.

Accounting to increasing cases of Covid-19 across the world, researchers are focusing on implementing preventive and precautionary measures through newer concepts. The excessive research associated with the use of genomics in Covid-19 pandemic has yielded a few successful measures. As a result, genomics has recently attracted attention from across the world.

The whole world is fighting the novel coronavirus. Sectors and industries are devasted due to the major loss caused by COVID-19 in business. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.

To get to know more about the short-term and long-term impacts of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941

Constant Product Innovations are Consequential to Increasing R&D Efforts

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Among all factors, the increasing number of product innovations, driven by rising investments in the research and development of the product, has made the highest impact on the growth of the market. In April 2020, Eurofins announced the launch of a new product in the genome sequencing space.

The company introduced SARS-CoV 2 full length genome sequencing, a product that is categorized under the next-generation (NGS) sequencing category. Increasing number of such product innovations will have a positive impact on the growth of the overall market in the coming years.

North America to Emerge Dominant; Increasing Activities associated with Whole-genome Sequencing will Emerge in Favor of Market Growth

The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing research activities associated with whole-genome sequencing by private companies as well as government organizations will contribute to the growth of the regional market.

As of 2019, the market in North America was worth USD 8.27 billion and this value is projected to rise at a considerable pace in the coming years. The market in Asia Pacific will derive growth form the efforts put in towards genetic sequencing by countries such as China.

Quick Buy - Genomics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100941

List of companies profiled in the Genomics Market report:

Industry Developments:

February 2020: Nebula Genomic announced the launch of a new product that will offer whole genome sequencing at US$ 299 to its customers.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/genomics-market-100941

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/genomics-market-100941

Have a Look at Related Reports:

Next-Generation Sequencing (NGS) Market Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026

Molecular Diagnostics Market Share and Global Trend By Product Type (Instruments Reagents & Consumables), Application (Infectious Disease, Blood Screening, Histology & Oncology), Technique (Hospitals Amplification, Hybridization & Sequencing Techniques), End User (Hospitals, Clinical & Pathology Labs) and Geography Forecast till 2025

Polymerase Chain Reaction (PCR) Market Share & Industry Analysis, By Type (Standard PCR, Real-time PCR, and Digital PCR), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026

Hormone Replacement Therapy (HRT) Market Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies), and Regional Forecast, 2019-2026

Heart Valves Market Share & Industry Analysis, By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/genomics-market-9172

See the rest here:
Genomics Market to Rise at 19.5% CAGR and Reach USD 82.60 Billion by 2027; Advances in Diagnostic Applications will Lead to a Wider Product Adoption,...

Read More...

Are there ethical ways to use animals in medical research? – Federal News Network

September 28th, 2020 4:59 pm

Best listening experience is on Chrome, Firefox or Safari. Subscribe to Federal Drives daily audio interviews onApple PodcastsorPodcastOne.

This topic can get emotional: Should animals be used in medical research? Now recently I aired an interview that was critical of the Veterans Health Administration for its use of cats in research experiments related to the bodily functions of paraplegics. VHAdid submit a rebuttal statement but the agency has not responded to requests for an interview. Americans for Medical Progress is an organization that advocates in favor of the ethical use of animals in medical research.Executive Director of Paula Clifford andCommunications Director Jim Newman joinedFederal Drive with Tom Temin.

Tom Temin:Alright, lets get right to this. Can animals be ethically used for research? We know they are, but is this something that has value in medical research?

Paula Clifford:Absolutely. I started out in research as a veterinary technician. And at that time, I was just doing an externship. I was a student, and I thought I would do my externship and go and spend my career working at a veterinary hospital. But during that time, I found that as a veterinary technician, I could dedicate my life to taking care of the animals that actually take care of people and other animals through research with them.

Jim Newman:And my early career experience was working at universities. I first worked at an institution in Oregon and then I worked for a cancer center. And what I learned from those experiences is that animals play a tremendously important role in developing treatments, I literally watched as cancer medications were developed, or new ways to treat patients were created through animal studies, or discovered through animal studies. And so thats one of the reasons I remain involved in this field is that I had first hand experience seeing the importance of this kind of research.

Tom Temin:And how is this done such that the animals dont suffer too much, in general?

Paula Clifford:Animals in research are cared for, a very large team of animal care professionals. And this is everybody from highly trained animal care technicians that do their day-to-day care. So feed, water, cleaning, and daily observations. And then you have veterinary technicians like me, who will then respond to any abnormal report. So if you have an itchy mouse, or a dog thats not eating normally, or a monkey thats behaving differently, that gets triaged to the vet care team. So the veterinary technician will check the animals out and then report that to the veterinarian who will come and diagnose and treat the animal.

Tom Temin:Well, let me ask you this, are there industry standards in the research community for how animals should be treated? Is there some sort of a certification program or any kind of inspection oversight that happens in facilities where animals are used in research?

Paula Clifford:Absolutely. So under the Animal Welfare Act, most animals are covered under that act. And that requires the USDA the United States Department of Agriculture to do at least an annual unannounced inspection to make sure that the animal care is compliant with those federal laws. But not all animals are covered under that act. But most animals are covered under the PHS policy, which needs to be followed by any institution that receives any government funding.

Tom Temin:PHS stands for ?

Paula Clifford:Public Health Service. So the majority of animals are covered under one of those two things. But there are some animals that are not and theres another layer, which is a voluntary accreditation by AAALAC International, and that really holds institutions at even higher standards. And they follow really detailed animal care protocols in a document called the guide for laboratory animal use.

Tom Temin:Jim, anything to add?

Jim Newman:I would just add that in addition to all of those external controls, there are internal controls at every institution, so as you probably can guess, there are inspections of facilities, and those are surprise inspections, but they cant be inspected every single day. So every institution is required to have its own system for monitoring how animals are cared for. And when you hear about something that happens, which is a rare thing that often is because the institution itself said, oh, heres an issue we need to address. So there are actually internal controls, as well as external controls to help ensure that animals are treated well.

Tom Temin:Were speaking with Jim Newman, hes the communications director, and with Paula Clifford, the executive director of Americans for Medical Progress. And again, you cant speak for what happens inside Veterans Affairs, but in your observations over the years, have the federal facilities that use animals in testing and there are quite a number of them generally follow these guidelines, including the federal ones?

Jim Newman:Absolutely. In fact, I was looking a little bit at the VAs research and it stands out for many reasons. One is that 99% of the research that the VA does is in rats and mice. Now you hear a lot of talk about other animals, and thats because the animal rights groups like to talk about that. But 99% is in, again, rats or mice, and in those very rare cases where they study other animals such as cats or dogs, theres a good reason for that its because those animals are specifically necessary for the kinds of studies that are conducted and looking at the list of achievements from the VA is pretty remarkable. Theyve been able to help veterans who receive spinal cord injuries that help them breathe, help them cough to clear their breathing channels. Bladder control is another issue that happens when you lose, you know, the ability to move your limbs. Thats something theyve helped them with. Artificial pancreas, organ transplants the list is 20 or 30 major items that have been accomplished through animal studies. So the VAs research is incredibly remarkable. Anybody who would like to do some research on it should really look at their site, because what theyre doing his outstanding research that actually helps both veterans but also all Americans.

Tom Temin:And Paula, what is it that your organization does to kind of get this word out? I mean, Americans for Medical Progress could cover almost any topic.

Paula Clifford:Sure. So a lot of what we do is we actually help those working with the animals either on the animal care side or the researcher side, to help them tell their story and share with the public really what its like to work with animals and research, why, when and how animals are involved in research. We also do a lot of work with institutions to help them engage with the public and really share, you know, what is it about animals that make it so necessary and so important to advance biomedical progress?

Tom Temin:I once spoke to a dairy farmer in a story I did is a very young reporter very many years ago. And they had, I dont know, 50 or 60 cows in this barn. And at the end of the cows life, I said, what happens when the cow gets too old? They said, well it becomes meat. I said, but dont you kind of get attached to them? They all have names hanging on their necks. And the farmer it was the wife of the farmer, I guess she was a farmer, too said, Well, we just consider it their final gift to us when they become steaks. And so not to get too touchy feely here, but people that handle animals in experimental situations, what kind of relationship do they have with the animals, do you think?

Paula Clifford:Oh, gosh, I can tell you what I know for sure. You certainly do get attached. I can share personal stories. And theres, if you talk to anybody who works with animals in research, they also do get attached. They have names. And often they do have to be euthanized at the end of the study. Because in order to get the data from the study, you need to look at the cellular level, you need to maybe take out the heart or look at the bladder. So thats really difficult. Any area of veterinary medicine can be heartbreaking, theres really rewarding and happy times. And theres really emotional and sad times. So theres crying that happens as well, because you do get attached to the animals and the end of study does come but we know that like the dairy farmer, it is their final gift to us. And not only will they be helping the scientists with their data, but the humans that will benefit from the data. And often the advancements that happen for humans also go on to benefit our pets as well: Surgical techniques, vaccines, medicines and multiple other types of advancements.

Tom Temin:And Jim, I guess people that are involved in this kind of work are also pet owners themselves, arent they?

Jim Newman:Thats very true. A lot of people enter animal care, for instance, because they want to work with animals, they want to be up close with them every single day. And you know, Americans, I think the percentage of Americans that own pets and love their pets is incredible. And of course, that includes scientists and animal care technicians. And anybody who works in a research facility. People who work with animals at work, also love those animals at work and at home. And theres some assumptions that people who work with animals in a research setting dont like animals, thats actually the opposite. The truth is that they love the animals they care for. And they probably go home to some of the pets that they also love just as much.

Paula Clifford:Yeah. And just to add, in some cases, when the study is complete, and the animal does not need to be euthanized, they get adopted. So I adopted a dog from research. He was on a pacemaker study, and he lived with us. I adopted him at seven and he lived with us until he at the end of his life of 15. So theres countless stories of researchers and animal care staff, veterinarians, veterinary technicians that adopt the animals that are able to be adopted when their study has ended.

Tom Temin:Paula Clifford is executive director of Americans for Medical Progress. Thanks so much for joining me.

Paula Clifford:It was a pleasure, thank you so much.

Tom Temin:And Jim Newman is the communications director. Jim, thank you.

Jim Newman:Thank you, sir.

Tom Temin:Well post this interview at FederalNewsNetwork.com/FederalDrive. Hear the Federal Drive on demand. Subscribe at Apple Podcasts or Podcastone.

Link:
Are there ethical ways to use animals in medical research? - Federal News Network

Read More...

Texas A&M VET Mobile Team Deploying To California To Assist With Wildfire Relief – Texas A&M University Today

September 28th, 2020 4:59 pm

Nine members of the Texas A&M Veterinary Emergency Team (VET) and six agents from the Texas A&M AgriLife Extension Service will be deploying to Butte County, California on Saturday to help care for animals displaced by the ongoing wildfires.

The VET deployed to the same area last December to provide oversight on sheltering, inventory and data management, veterinary medical support for injured and ill animals, and efforts to reunite animals with their owners.

Our deployment to the camp wildfires in December 2018 and January 2019 set the stage for this request, said VET director Dr. Wesley Bissett. We have a close working relationship with the community we are being deployed to and our capabilities are well known to them.

Our primary role will be to provide consistency in operational management and veterinary medical care, he said. They have an outstanding group of people at the local level and I know we will all work together for the sake of the animals, their owners, and Butte County, California.

The teams mission will be to support three area shelters that have taken in almost 500 animals that have been displaced by the wildfires. The VET will bring their experience in managing emergency shelters and situations to help ease the stress being put on the local responders. The initial team deploying includes four veterinarians, two veterinary technicians, and three logistics and support personnel.

Anytime you go into out-of-state deployments, there is an element of uncertainty that is based on being so distant from the impact area, Bissett said. There is always a discovery phase during which you work to understand, specifically, what is needed so that your team can contribute to the success of the jurisdiction you are serving.

This isnt the first time this year that the VET has assisted with the ongoing wildfire efforts. Dr. Deb Zoran, VET member and professor in the Texas A&M College of Veterinary Medicine & Biomedical Sciences, recently deployed to Oregon to assist with the Texas A&M Task Force search and rescue dogs working in a particularly hazardous area.

For updates on the deployment, follow the VET on Facebook (@TAMUVET) and Twitter (@tamuvet1) and at tx.ag/VETteam.

Link:
Texas A&M VET Mobile Team Deploying To California To Assist With Wildfire Relief - Texas A&M University Today

Read More...

Molly the Fire Safety Dog needs help with vet bills after medical emergency – Dog of the Day

September 28th, 2020 4:59 pm

Molly the Fire Safety Dog, one of the bigger names on Dog Twitter, could use some help with vet bills after a medical emergency this weekend.

Molly is an 8 year oldDalmatian from Clarksville, Arkansas who puts together livestreamed (and in-person when pawsible) demonstrations on fire safety for elementary students around the US and Canada through her Keep Kids Fire Safe Foundation.

While doing a livestream on her Facebook page on Saturday night, she possibly had a seizure or a stroke, which meant rushing over to an emergency animal hospital two hours away and an overnight stay.

Her blood pressure was checked out overnight, and she needed to visit an animal ophthalmologist (eye doctor specializing in medical care) on Sunday afternoon, which was a branch of veterinary medicine we didnt realize existed.

Im sitting outside hoping and praying the doc has good news, Mollys mom Dayna Hilton toldDog ODayon Sunday afternoon.

Becausevet bills are pricey at the best of times, and emergency procedures especially so, they would welcome PayPal donationsif you have the means to donate.

Everyone is so supportive and friendly, our palPeytonReads said earlier this year while talking about the kindness of Dog Twitter. Its more than positiveit is genuinely heartfelt care and concern. We gather and celebrate when someone is happy. We gather and offer support when someone is sad.

Molly was able to return home on Sunday night, and seemed exhausted but calm in a photo she shared.

Goodnight, everyone. Thanks for all the love and prayers you have sent my way, she wrote in the caption.

Molly was one of the recipients of the2019 ACE Awards(the American Kennel Clubs Award for Canine Excellence) in the Exemplary Companion Dog category, and she had a small role in the 2019 documentarySuperpower Dogs.Shes also the official ambassador ofSuperpower Dogs,and the mascot of the Keep Kids Fire Safe Foundation.

Close to home within the River Valley region of Arkansas, though, shes still the firedog for the local volunteer fire department, so she doesnt let the fame get to her head, even if she is friends with Bunsen the Science Dog and Sampson the Service Dog, not to mention an array of high-profile human members of Dog Twitter like Ive Pet That Dogs Gideonand Britishpet artist Iain Welch.

We hope Molly the Fire Safety Dog feels better soon, and that the kindness of the Dog Twitter community can help out with her vet bills.

Follow this link:
Molly the Fire Safety Dog needs help with vet bills after medical emergency - Dog of the Day

Read More...

‘Really hard to let go’: Grimsby veterinarian easing into retirement after 32 years – Niagarathisweek.com

September 28th, 2020 4:59 pm

As a veterinarian, on a daily basis, were covering the grounds of treating and diagnosing medical conditions and also doing any surgeries that are required, also interacting with clientele, doing a lot of preventative care, a lot of puppy kitten work as well as older patients, so theres a wide variety in what you do every day, she says.

Cline has honed in her analytical side over the years, relying more on her intuition and experience, but its not just the animals suffering to worry about.

In the case of the hamster, Cline also mentions the bond that had formed between a young girl and the pet.

Theres that kind of unconditional love that they give you, they have needs and you provide for them; you get that positive feeling from that, and theyre just total affection, total love really, but a different kind than human love, she says of the bond between animals and humans.

For her, the two are inseparable.

I guess I love people and I love pets too. Veterinary medicine gives me that combination where I can interact with people in that capacity which I just love, she explains.

Truth be told, Cline isnt keen about her semi-retirement and talking about it makes her uncomfortable. But the pandemic has dramatically changed some of what she loves most about her job.

I like to practise in a very personal way, I like to focus on the client thats in (the room) and that pet and not be pressured or stressed or time restricted, she says. Its really hard to let go completely.

So, shes letting herself down slowly.

Shell miss her co-workers and the community work through the hospital raising awareness and funding for the Farley Foundation, which provides monetary support for those who struggle to pay for veterinary care.

Occupying her time isnt going to be a challenge. Between playing saxophone in two bands the Lincoln County Band & Jimmy Marando Swing Band gardening, and weekending at the cottage, she still plans on fitting in some time at the hospital.

At home, its an empty nest with John (her three boys are now grown and moved out) but shell be seeing more of her fur children an active Jack Russell terrier rescue and a former stray kitten, Tiger, who is now a grown 17-year-old.

While one door is slowly closing, another remains open in Clines heart should another animal be in need of the care and compassion that has, for so long, defined her work.

Its just about being able to serve, being able to provide. I think I really like to see a problem and solve the problem, she says.

Its just who she is.

View original post here:
'Really hard to let go': Grimsby veterinarian easing into retirement after 32 years - Niagarathisweek.com

Read More...

THANK YOU: Lambert says thank you to Yogi Crowe Scholarship – The Cherokee One Feather – Cherokee One Feather

September 28th, 2020 4:59 pm

Siyo, my name is Jessica Rose Lambert. I am the daughter of Kimlyn Sneed Lambert and the late Douglas Allen Lambert. I am from the Birdtown community, and a 2014 graduate of Cherokee High School and 2017 graduate of WCU. It has always been my life-long dream of mine to become a veterinarian. I am currently in my second year of attending post-graduate school at North Carolina State University in Raleigh, earning my Doctor of Veterinary Medicine Degree. It is my hope that one day I may be able to come back to the Qualla Boundary and open my own veterinary practice there. I would love to one day be able to help the people on the reservation with their pet care needs. I would also like to encourage EBCI students to consider becoming a Veterinarian, it is a great profession if you love animals like I do. I would like to personally thank the Yogi Crowe Scholarship for helping with my costs of living in Raleigh and for helping to make my dream a reality. They have generously provided funding that makes it possible for graduate students like me to make ends meet while attending school. Thank you again so very much!

Jessica Lambert

N.C. State Vet School Class of 2023

Original post:
THANK YOU: Lambert says thank you to Yogi Crowe Scholarship - The Cherokee One Feather - Cherokee One Feather

Read More...

Livestock, wildlife health focus of UW position Sheridan Media – Sheridan Media

September 28th, 2020 4:59 pm

(Courtesy photo)

Kerry Sondgeroth, an associate professor and veterinary bacteriologist, accepted the position this month as the Riverbend Endowed Professor of Wildlife-Livestock Health at the University of Wyoming.

Sondgeroth, who comes from the Wyoming State veterinary laboratory, said the position has the potential to have an immense benefit on Wyomings livestock and wildlife.

She said she hopes the position will build a solid reputation at UW for wildlife-livestock health and bring awareness to the diseases being studied. Her appointment to the position is for five years.

Sondgeroth said the position can be a middle ground to gain understanding of certain diseases in order to protect the health of wildlife, livestock and humans.

Tim Mellon donated the Riverbend Ranch west of Laramie to the UW Foundation in 2011, with proceeds of the ranchs eventual sale earmarked to establish the endowment position in UWs College of Agriculture and Natural Resources.

Sondgeroth received her doctor of veterinary medicine degree from Colorado State University in 2006 and was a post-degree graduate student at Washington State University from 2006-13. She received a Ph.D. in veterinary science in 2013.

She said her training and position as the only veterinary bacteriologist in Wyoming provides exposure to many bacteriological diseases across the state of interest to livestock producers and wildlife interest groups.

Link:
Livestock, wildlife health focus of UW position Sheridan Media - Sheridan Media

Read More...

Fastest-growing jobs that pay over $100K | Your Money – jacksonprogress-argus

September 28th, 2020 4:59 pm

r preparing for graduation will enter a marketplace rife with uncertainty. Still, there are plenty of careers that have shown fast growth in recent years and pay salaries of six figures or more.

Stacker breaks down 50 of these industries, the prerequisites for entering those fields, and how those jobs have been affected over the past year. We compiled a list of 50 fastest-growing jobs with average salaries of over $100,000 using 2019 data from the Bureau of Labor Statistics Employment Projections (released Sept. 1, 2020) and Occupational Employment Statistics (released March 31, 2020). The jobs are ranked by their 10-year projected employment change, and ties are broken by the projected employment in 2029. Any broad or vague groupings of jobs, as well as jobs that have "all other" in the name, were omitted from the list, as they do not reflect an accurate portrayal of one specific occupation.

The jobs listed in this article include transportation workers, judges and lawyers, and a bevy of STEM jobs (mathematicians, physics professors, and chemical engineers, to name a few). Different physicians and tech industry workers also make several appearances. Many of these professions necessitate postsecondary education or on-the-job training. Of course, more opportunities for lower-income citizens to gain access to these jobs are a growing concern for more Americans, as well as the need to invest in STEM education in communities that dont have the same resources as more affluent communities.

Click through to find out which fast-growing jobs might be of interest to you, a family member, or even a youngster you may know whos planning for the future, and be sure to check out Stackers other articles about the job market.

You may also like: Most popular college majors in America

The rest is here:
Fastest-growing jobs that pay over $100K | Your Money - jacksonprogress-argus

Read More...

Free pet vaccinations offered this weekend in Seattle & around the Sound – Talk Radio 1210 WPHT

September 28th, 2020 4:59 pm

The past few months have proven to be challenging for almost everyone, and that includes pet owners who may be struggling to keep up with regular veterinary care for their animals.

It's not a stretch to understand that when the budget gets tight, pet vaccinations don't seem as essential as they once might have been.

Inspired in part by the fact that World Rabies Day is coming on Monday, acoalition of veterinary clinics and animal care providers in and around Seattle, in partnership with the WSU College of Veterinary Medicine, are holding the first-ever multi-site vaccination effort known as One Health Clinic.

This Saturday, September 26th from 1pm-4pm,they'll be helping low-income pet owners or people experiencing homelessnesswith access to pet food and veterinary care for their beloved animal companions.

As a post from Seattle Humane says: COVID-19 has made it harder for many folks to keep up with vet appointments, both due to financial hardship and accessibility issues. We are concerned about the number of Parvovirus cases being reported in the community. We will be offering the Parvo vaccine on Saturday during a multi-site vaccine clinic as part of World Rabies Day. We will be joined by several local shelters, nonprofits and government entities in offering these free clinics at five different locations from 1-4 p.m. Saturday.

The locations and the providers:

Health and safety is a key priority for these events, so strict adherence to mask-wearing, physical distancing, and hand sanitizing is expected.

Please help spread the word, as these organizationsaim to provide critical veterinary care to the animals who need it most during these unprecedented times.

See the rest here:
Free pet vaccinations offered this weekend in Seattle & around the Sound - Talk Radio 1210 WPHT

Read More...

Twenty-Five Year Club: New Members for 2020 | University of Pennsylvania Almanac – UPENN Almanac

September 28th, 2020 4:59 pm

Twenty-Five Year Club: New Members for 2020

Since 1956, Penn has celebrated a rite of passage each year for faculty and staff who meet one common requisite: they have been members of the University community for 25 years. Another 163 new members crossed the 25-year mark in 2020. Although we wont be holding areception this year, we want to honor these employees and thank them for their commitment to Penn.

Division of Human Resources

N. Scott Adzick, Perelman School of MedicineDan Alig, Wharton SchoolJane Anderson, Perelman School of MedicineTerry Anderson, Perelman School of MedicineHaimanti Banerjee, Wharton SchoolBryant Barr, Facilities and Real Estate ServicesSarah Barr, Provost Interdisciplinary ProgramsJames Berger, Perelman School of MedicineEdward Bergman, Wharton SchoolHema Bhargava, Perelman School of MedicineAregawi Biru, Facilities and Real Estate ServicesEve Bosnick, School of NursingJennifer Bottomley, School of Arts and SciencesEric Bradlow, Wharton SchoolJoseph Breslin, School of Dental MedicineKathleen Brown, School of Arts and SciencesLoretta Brown, University LibraryBeverly Browne, Facilities and Real Estate ServicesRichard Cardona, Annenberg School for CommunicationMichele Carlin, Perelman School of MedicineLatanya Carter, Business ServicesJoseph Carver, Perelman School of MedicineLorene Cary, School of Arts and SciencesBenjamin Chang, Perelman School of MedicineYouhai Chen, Perelman School of MedicineArtur Cideciyan, Perelman School of MedicineJames Clavin, Division of FinanceTheresa Colligon, Perelman School of MedicineSherrie Cornish, Residential and Hospitality ServicesJulia Crane, School of Arts and SciencesBarbara Dallap Schaer, School of Veterinary MedicineAnnet Davis, Perelman School of MedicineCarmen De La Rosa, School of Arts and SciencesLeah Dennis, School of Arts and SciencesFrancis Deroos, Perelman School of MedicineMaiheng Dietrich, School of Arts and SciencesWinka Dubbeldam, Weitzman School of DesignMaryellen Eckenhoff, Perelman School of MedicineScott Edwards, Perelman School of MedicineRicardo Eiraldi, Perelman School of MedicineRonit Engel, School of Arts and SciencesStanford Ewing, Perelman School of MedicineAutumn Fiester, Perelman School of MedicineChioma Fitzgerald, Perelman School of MedicineJames Foskett, Perelman School of MedicineDouglas Fraker, Perelman School of MedicineRobert Gallop, Perelman School of MedicineArupa Ganguly, Perelman School of MedicineNoah Gans, Wharton SchoolJ. Gaynor, Perelman School of MedicineJames Gee, Perelman School of MedicineMaria Gifoli, Facilities and Real Estate ServicesCatherine Gontarek, Development and Alumni RelationsKathleen Hall, Graduate School of EducationJason Hart, Facilities and Real Estate ServicesGus Hartman, School of Arts and SciencesKaren Hirschman, School of NursingJoanne Inverso, Perelman School of MedicineSamuel Jacobson, Perelman School of MedicineStephanie Johnson, Perelman School of MedicineCynthia Johnson-Mollen, Perelman School of MedicineRandall Kamien, School of Arts and SciencesHillary Kane, School of Arts and SciencesAyako Kano, School of Arts and SciencesMarcelo Kazanietz, Perelman School of MedicineMary Kelly, Perelman School of MedicineDaniel Kessler, Perelman School of MedicinePeter Klein, Perelman School of MedicinePamela Knight, Wharton SchoolLaura Kosseim, Perelman School of MedicineVicky Kresge, Wharton SchoolPauline Kulynych, School of Arts and SciencesBarbara Lang, Perelman School of MedicineRobert Lawler, Information Systems and ComputingHae-Rhi Lee, Perelman School of MedicineJulie Leu, Perelman School of MedicineTrevor Lewis, General University SpecialJanet Lioy, Perelman School of MedicineGregg Lipschik, Perelman School of MedicineHuan Lou, School of Dental MedicinePing Loveland, Penn GlobalJohn Macdermott, School of Arts and SciencesRosemary Malague, School of Arts and SciencesRichard Maniglia, Perelman School of MedicineRichard Marcantuno, School of Veterinary MedicineMichael Marks, Perelman School of MedicineJerome Marrow, Facilities and Real Estate ServicesNicola Mason, School of Veterinary MedicineGiacomina Massaro-Giordano, Perelman School of MedicineDeborah Mathis, Student ServicesThomas Mccaffery, Information Systems and ComputingJoseph Mclaurin, Information Systems and ComputingJon Merz, Perelman School of MedicineStephen Metraux, Perelman School of MedicineBonnie Milas, Perelman School of MedicineJaime Miller, School of Veterinary MedicineClaire Mitchell, School of Dental MedicineFrank Moore, Facilities and Real Estate ServicesDiedre Morrison, Division of Public SafetyAnn Moyer, School of Arts and SciencesMary Mullins, Perelman School of MedicineDavid Musto, Wharton SchoolAnn OBrien Jenkins, Perelman School of MedicineKim Olthoff, Perelman School of MedicineOlga Ortiz, Perelman School of MedicineAnthony Pagano, Facilities and Real Estate ServicesFelicity Paxton, Annenberg School for CommunicationLouise Pedraz, Human ResourcesMartha Penny, Perelman School of MedicineAnn Perch, Wharton SchoolMichael Perillo, School of Dental MedicineJeanmarie Perrone, Perelman School of MedicineChristopher Petro, Perelman School of MedicineRebecca Phillips, School of NursingLoretta Picklo, Facilities and Real Estate ServicesDonald Pijak, Perelman School of MedicineMary Pipan, Perelman School of MedicineAnne Pomerantz, Graduate School of EducationJ.Russell Ramsay, Perelman School of MedicineTarik Richardson, Wharton SchoolMary Ritchie, Information Systems and ComputingLouis Rulli, Law SchoolPaul Ryersbach, University LibraryBernadette Salera, Perelman School of MedicineMohnednur Salih, Business ServicesBarbara Savage, School of Arts and SciencesSusan Schachtner, Perelman School of MedicineTheresa Schuck, Perelman School of MedicineJonathan Schug, Perelman School of MedicineStacey Secreto-Dankanich, School of Dental MedicineAbraham Shaked, Perelman School of MedicineAllen Shinn, Perelman School of MedicineDouglas Sloane, School of NursingPam Smith, Perelman School of MedicineWenchao Song, Perelman School of MedicineShobana Sood, Perelman School of MedicineMichele Souli, School of Arts and SciencesLaura Sprague, School of Dental MedicineSusan Staggs, Provosts CenterHolly Stefanow, Perelman School of MedicinePaul Stephens, Perelman School of MedicineAlan Strudler, Wharton SchoolTomoko Takami, School of Arts and SciencesJian-Qin Tao, Perelman School of MedicineGihan Tennekoon, Perelman School of MedicineJoanne Thorvaldsen, Perelman School of MedicineDavid Toccafondi, University LibraryDonald Tsai, Perelman School of MedicineGregory Van Duyne, Perelman School of MedicineAntonia Villarruel, School of NursingKevin Walker, School of Arts and SciencesDonna Walter, Facilities and Real Estate ServicesAnn Webb, Development and Alumni RelationsFrederick Webb, Facilities and Real Estate ServicesJanet Weiner, Perelman School of MedicineTimothy Wells, University LibraryE. Wileyto, Perelman School of MedicineYin Wong, School of Social Policy and PracticeBarbara Woodford, School of Arts and SciencesYanjie Yi, Perelman School of MedicineXiuqin Zhou, University MuseumHongming Zhuang, Perelman School of MedicineEmily Zug, School of Veterinary Medicine

See the original post:
Twenty-Five Year Club: New Members for 2020 | University of Pennsylvania Almanac - UPENN Almanac

Read More...

Veterinary Weighing Platforms Market Size, Share 2020 Growth Analysis, Share, Demand By Regions, Types And Analysis Of Key Players- Research Forecasts…

September 28th, 2020 4:59 pm

A veterinary is related to diseases, injuries and treatment of farm, domestic or wild animals. Veterinary industry is mainly because of increased pet ownership, awareness of animal health issues, demand for animal related products and the availability of advanced surgical and diagnostic procedures. There are various technologies involved in veterinary medicine. Nowadays, animal health product such as metabolic drugs, anti-infective, reproductive aids, feed additives, vaccines, imaging diagnostics, topical solutions and parasite controls are becoming more popular.

Market Research Engine has published a new report titled as Veterinary Weighing Platforms Market Size By Application (Veterinary Hospitals, Veterinary Clinics, Home Use), By Type (With Digital Display, Separate Indicator), By Region (North America, Europe, Asia-Pacific, Rest of the World), Market Analysis Report, Forecast 2018-2024.

Browse Full Report: https://www.marketresearchengine.com/veterinary-weighing-platforms-market

In animal hospitals and clinics, the doctors treat injuries and disease of animals, but get most of the revenue from animal health procedures such as neutering and spaying, vaccinations, and regular checkups. Veterinary Weighing Scale is used to weigh pets weight for correct dosage of medicine and also to check healthy growth.

Market Insights

The global Veterinary Weighing Platforms market is segregated on the basis of Application as Veterinary Hospitals, Veterinary Clinics, and Home Use. Based on Type the global Veterinary Weighing Platforms market is segmented in With Digital Display and Separate Indicator.

The global Veterinary Weighing Platforms market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Veterinary Weighing Platforms market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Befour, Inc, Bosche GmbH & Co.KG, Detecto Scale, DRE Veterinary, Horse Weigh, KERN & SOHN, Leading Edge, Marsden Weighing Machine Group, Shor-Line, SR Instruments, and others are among the major players in the global Veterinary Weighing Platforms market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Veterinary Weighing Platforms Market has been segmented as below:

Veterinary Weighing Platforms Market, By Application

Veterinary Weighing Platforms Market, By Type

Veterinary Weighing Platforms Market, By Region

Veterinary Weighing Platforms Market, By Company

The report covers:

Report Scope:

The global Veterinary Weighing Platforms market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Veterinary Weighing Platforms market share. Major industry players with significant revenue share include Befour, Inc, Bosche GmbH & Co.KG, Detecto Scale, DRE Veterinary, Horse Weigh, KERN & SOHN, Leading Edge, Marsden Weighing Machine Group, Shor-Line, SR Instruments, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/veterinary-weighing-platforms-market

Table of Contents:

Other Related Market Research Reports:

Electronic Veterinary Weighing Scale Market 2019|Top Key Players Analysis, Trends, Global Size Forecast To 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read the original here:
Veterinary Weighing Platforms Market Size, Share 2020 Growth Analysis, Share, Demand By Regions, Types And Analysis Of Key Players- Research Forecasts...

Read More...

COVID-19 canines: How dogs may help sniff out the coronavirus in humans – ABC News

September 28th, 2020 4:59 pm

September 24, 2020, 11:10 PM

4 min read

They say you can't teach an old dog new tricks, but trainers in Finland claim 8-year-old greyhound mix Kssi learned to identify a scent associated with COVID-19 in just seven minutes.

Helsinki Airport welcomed Kssi and nine other "coronavirus-sniffing dogs" as part of a pilot program this week meant to "speed up the process of identifying those infected with COVID-19."

Trainer Susanna Paavilainen is seen with Kossi (L) and Miina, sniffer dogs being trained to detect COVID-19 from the arriving passengers' samples, at Helsinki Airport in Vantaa, Finland, Sept. 22, 2020.

"We are among the pioneers," Helsniki Airport director Ulla Lettijeff said. "As far as we know, no other airport has attempted to use canine scent detection on such a large scale against COVID-19."

Four dogs will work at the airport during a shift, but passengers getting tested will not have direct contact with the dogs.

They will be prompted to swipe their skin with a wipe and drop it into a cup, which is then given to the dog to smell.

"The service is mainly intended for passengers arriving from outside the country," Susanna Paavilainen, CEO of WiseNose Ry, University of Helsinki's DogRisk research, explained.

Kossi, one of the sniffer dogs being trained to detect COVID-19 from the arriving passengers' samples, is seen at Helsinki Airport in Vantaa, Finland, Sept. 22, 2020.

The airport said that according to preliminary tests conducted by a research group at the Faculty of Veterinary Medicine at the University of Helsinki, "dogs are able to smell the virus with almost 100% certainty."

In the U.S., testing is still underway to determine if dogs can truly sniff out the coronavirus. The University of Pennsylvania's School of Veterinary Medicine (Penn Vet) launched a pilot study in April that would take a group of dogs and expose them to COVID-19-positive saliva and urine samples in a laboratory setting.

Once the dogs learned the odor, investigators would then see whether or not the animals can discriminate between COVID-19 positive and negative samples in a lab setting, according to Penn Vet.

While the results of the study have not yet been released, Penn Vet called it "pioneering" saying it "sets the stage for dogs to be a force multiplier in the mission to detect COVID-19, particularly among asymptomatic patients, or hospital or business environments where testing is most challenging."

Both the Transportation Security Administration (TSA) and U.S. Customs and Border Protection (CBP) told ABC News they are not training their canines to detect COVID-19.

See the original post here:
COVID-19 canines: How dogs may help sniff out the coronavirus in humans - ABC News

Read More...

Genomic Biomarker Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Bio-Rad, Beckman Coulter, Myriad Genetics,…

September 28th, 2020 4:57 pm

Latest research report, titled Global Genomic Biomarker Market Insights, Forecast to 2025. this report included a special section on the Impact of COVID-19. Also, Genomic Biomarker Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends .The report also gives 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the strength, weaknesses, opportunities, and threats in front of the businesses. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Genomic Biomarker markets to extend their reach and create sales opportunities.

Top Key players profiled in the report include:Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina and More

To Get PDF Sample Copy of the Report(with covid 19 Impact Analysis): https://www.globmarketreports.com/request-sample/4134

Genomic Biomarker market competitive landscape offers data information and details by companies. Its provides a complete analysis and precise statistics on revenue by the major players participants for the period 2020-2025. The report also illustrates minute details in the Genomic Biomarker market governing micro and macroeconomic factors that seem to have a dominant and long-term impact, directing the course of popular trends in the global Genomic Biomarker market.

Market Segment By Type:OncologyCardiologyNeurologyNephrology

Market Segment By Application:HospitalsDiagnostic and research laboratories

Regions Covered in the Global Genomic Biomarker Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

Get Chance of up to 30% Extra Discount @ https://www.globmarketreports.com/request-discount/4134

Some Major TOC Points:

For More Information with including full TOC: https://www.globmarketreports.com/industry-reports/4134/Genomic-Biomarker-market

Customization of the Report:Glob Market Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.globmarketreports.com/report/request-customization/4134/Genomic-Biomarker-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: [emailprotected]

See the original post:
Genomic Biomarker Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Bio-Rad, Beckman Coulter, Myriad Genetics,...

Read More...

Precision Medicine Software Market by Trends, Dynamic Innovation in Technology and 2025 Forecasts | Covid-19 Analysis – The Daily Chronicle

September 28th, 2020 4:57 pm

In this report, we analyze the Precision Medicine Software industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a prediction of its production and consumption in coming 2019-2024.

Request sample copy athttps://www.reportsintellect.com/sample-request/1055238?utm_source=apsters&utm_medium=24

At the same time, we classify different Precision Medicine Software based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Precision Medicine Software industry development trends and marketing channels are analyzed.Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key players in global Precision Medicine Software market include:SyapseAllscriptsQiagenRoper TechnologiesFabric GenomicsFoundation MedicineSophia GeneticsPierianDxHuman LongevityTranslational SoftwareGene42, IncLifeomic Health

Inquire for a Discount at https://www.reportsintellect.com/discount-request/1055238?utm_source=apsters&utm_medium=24

Market segmentation, by product types:Cloud-basedOn-premise

Market segmentation, by applications:Healthcare ProvidersPharmaceutical and Biotechnology CompaniesResearch Centers and Government InstitutesOthers

Market segmentation, by regions:North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

The report can answer the following questions:1. What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Precision Medicine Software?2. Who are the global key manufacturers of Precision Medicine Software industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?3. What are the types and applications of Precision Medicine Software? What is the market share of each type and application?4. What are the upstream raw materials and manufacturing equipment of Precision Medicine Software? What is the manufacturing process of Precision Medicine Software?5. Economic impact on Precision Medicine Software industry and development trend of Precision Medicine Software industry.6. What will the Precision Medicine Software market size and the growth rate be in 2024?7. What are the key factors driving the global Precision Medicine Software industry?8. What are the key market trends impacting the growth of the Precision Medicine Software market?9. What are the Precision Medicine Software market challenges to market growth?10. What are the Precision Medicine Software market opportunities and threats faced by the vendors in the global Precision Medicine Software market?

Objective of Studies:1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Precision Medicine Software market.2. To provide insights about factors affecting the market growth. To analyze the Precision Medicine Software market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.4. To provide country level analysis of the market with respect to the current market size and future prospective.5. To provide country level analysis of the market for segment by application, product type and sub-segments.6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Precision Medicine Software market.

About Us:-

Reports Intellect provides Research Reports for everything related to market research and market intelligence. We are aware of trade importance and market need in todays competitive world.

Our team works efficiently to fetch the most authentic research reports backed with perfect data figures that guarantee outstanding results every time for you and your business.

Whether it is the latest report from the researchers or a custom demand feel free to contact us. We are available 24 hours for our beloved clients.

Contact Us:

[emailprotected]

PH + 1-706-996-2486

Read more here:
Precision Medicine Software Market by Trends, Dynamic Innovation in Technology and 2025 Forecasts | Covid-19 Analysis - The Daily Chronicle

Read More...

Losing hair fast? Applying this natural solution to the scalp resulted in new hair growth – Express

September 28th, 2020 4:57 pm

Hair loss can be the result of complex environmental and genetic processes. In the former camp lies responses to stressful situations and certain cancer treatments. In the genetic camp is androgenetic alopecia - commonly known as pattern baldness. It usually runs in the family, which, on the face of it, seems dispiriting.

Fighting genetics may seem like a losing battle but evidence does suggest you can reverse this form of hair loss.

One strategy that has yielded surprising results is applying a melatonin solution to the scalp.

Most people will associate melatonin with sleep - the hormone plays a central role in the bodys sleep-wake cycle.

As the National Sleep Foundation explains, its production increases with evening darkness, promoting healthy sleep and helping to orient our circadian rhythm.

READ MORE:Hair loss treatment - Dr Sara explains the best type of shampoo to stimulate hair growth

Circadian rhythms are 24-hour cycles that are part of the bodys internal clock, governing important processes such as the sleep-wake cycle.

Theres evidence that the benefits of melatonin extend to treating hair loss.

This is because melatonin also affects hair growth, as the hair growth cycle in mammals is under circadian control, according to The Lifespan Research Institute, a research body that focuses on anti-ageing compounds.

"As with other circadian cycles, the hair growth cycle becomes dysregulated and lower in amplitude with age," explains the research body.

DON'T MISSThe breakfast food that could stimulate hair growth and lower your risk of hair loss[INSIGHT]How to live longer: A juice to fight against cancer, reduce wrinkles and boost longevity[TIPS]Four of the most common early warning signs of vascular dementia[INSIGHT]

In a randomised double-blind study of 40 women with hair loss, melatonin solution applied to the scalp increased hair growth significantly relative to placebo.

What's more, in a study published in the International journal of trichology, 1891 male and female patients with androgenic alopecia applied a topical melatonin solution for three months.

At three months 61 percent of patients had no hair loss, compared to 12.2 percent at the start; 22 percent had new hair growth at three months compared to four percent at baseline.

The incidence of seborrheic dermatitis also declined, from 34.5 percent at baseline to 9.9 percent at three months.

Seborrheic (seb-o-REE-ik) dermatitis is a common skin condition that mainly affects your scalp.

The skin condition can cause an itchy, flaky rash, which may lead to hair loss due to excessive itching.

According to the NHS, finasteride and minoxidil are the main treatments for male pattern baldness.

"Minoxidil can also be used to treat female pattern baldness. Women shouldn't use finasteride," explains the NHS.

There are a number of drawbacks to consider before taking these treatments.

According to the NHS, these treatments:

These treatments:

Alternatively, some wigs are available on the NHS, but you may have to pay unless you qualify for financial help.

While considering your options, you may benefit from some psychological support.

Your GP may be able to help you get some counselling or you can join a support group, adds the NHS.

See the original post:
Losing hair fast? Applying this natural solution to the scalp resulted in new hair growth - Express

Read More...

Page 369«..1020..368369370371..380390..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick